Flashcards in Types of ovarian cysts Deck (19)
Definition borderline tumour
Tumours of low malignant potential with higher proliferative activity but without stromal invasion
Noninvasive neoplasms that occasionally have intraperitoneal spread
Six subtypes of borderline ovarian tumours
borderline Brenner tumor
Describe malignant potential of borderline ovarian tumours
BOT can be associated with microinvasion, intraepithelial carcinoma, lymph node involvement, and non-invasive peritoneal implants
Prognosis for BOT
- majority of BOT are limited to the ovary(ies) at presentation - 75% being diagnosed at FIGO stage I, compared to only 10% of ovarian carcinomas diagnosed at an early stage.
10-year survival of 97% for all stages combined
recurrences and malignant transformation can occur
- The 5-year survival rates for:
- stage I borderline: vary from 95–97%.
- stage III: 50–86%.
The 10-year survival rates range from 70–80%, owing to late recurrence
Treatment for Borderline ovarian tumours
-Complete surgical resection
- Surgical staging including omentectomy, peritoneal biopsies, cytology of peritoneal washings, and appendectomy in case of mucinous BOT
- Chemotherapy not indicated
Serous borderline tumours
- Most common (50%)
- Often bilateral (30%)
- Share similar histological features to low grade serous carcinomas
- May be a spectrum of cystadenomas - BOT - low grade serous adenoma
- Can be associated with extra-ovarian lesions
(also called implants), which can be invasive or non-invasive
Mucinous borderline tumours
- Second most common (46%)
- Either intestinal (86%) or endocervical/mullerian
- 10% associated with peritoneal pseudomyxoma
- Can be indistinguishable from appendiceal tumours therefore also need to review appendix
Tumors are usually large, unilateral, and cystic with a smooth ovarian surface, composed of multiple cystic spaces with variable diameter.
The cysts are lined by columnar mucinous epithelium of gastric or intestinal differentiation, with papillary or pseudopapillary infoldings, and admixed goblet cells and neuroendocrine cells
Risk factors for BOT
- Younger age
No evidence of increased or decreased risk:
- BRCA mutation
- Contraceptive pill use
Describe difference between two main types of ovarian ca and the relationship with BOT
- High grade serous has changes to P53
- Low grade serous due to mutations of BRAF/KRAS pathway- BOT are on this spectrum
Histological features of BOT
Histological features are defined by epithelial cellular
proliferation greater than that seen in benign tumours.
Borderline ovarian tumours have a stratified
epithelium with varying degrees of nuclear atypia and increased mitotic activity; their lack of stromal invasion distinguishes them from invasive carcinomas
Treatment for women with BOT:
- Desire to retain fertility
- No desire to retain fertility
1. Retain fertility:
- Early stage? - conservative surgery
- Late stage? - If invasive implants then complete surgery and follow up.
If no invasive implants then consider conservative surgery with close follow up
Need to counsel re risk of recurrence and future fertility
Consider complete surgery after family complete
2. No desire to complete fertility:
- Complete surgery with close follow up
- exploration of the entire abdominal cavity with peritoneal washings
- infracolic omentectomy
- appendicectomy in the case of mucinous tumours
Either cystectomy or USO + washings
Tumour markers in BOT
Serum CA125 levels may be raised:
- may have a high level in 75% of
serous and 30% of mucinous borderline ovarian tumours.
CA19-9 levels are frequently raised in mucinous
borderline ovarian tumours.
Other tumour markers such as
CEA, CA15-3 and CA72-4 may help detection but are not specific and may be within normal limits or only minimally elevated.
RMI status often low as many borderline ovarian tumours occur in younger, premenopausal women,
What to do if a BOT is identified after surgery
Referral to the regional cancer centre
followed by discussion at MDM.
Further management is planned according to the histology, grade, stage, DNA ploidy status (DNA aneuploidy carries higher risk of dying),
fertility preferences and completeness of primary surgery.
Recurrence rates dependent on surgical management
- Cystectomy 12-58%
- USO 0-20%
- Radical surgery 2.7-5.7%
Fertility outcomes after treatment of borderline ovarian tumours
no adverse effect of pregnancy on the disease or
Spontaneous fertility rates reported in literature
vary between 32–65%, with nearly half of the women treated conservatively conceiving spontaneously
Role of laparoscopy in BOT
- development of port-site metastases
- understaging of disease;
- higher risk of recurrence and worsened survival
Therefore should ideally be performed by laparotomy
IOTA explanation of 6 cysts seen on USS
Simple cyst: unilocular, no internal material (anechoic), thin walled and avascular.
Corpus luteum: unilocular with peripheral vascularity (‘ring of fire’), second half of the cycle and associated with a secretory endometrium (unless there is a Mirena insitu). These often appear haemorrhagic.
Haemorrhagic cyst: unilocular, reticular pattern of fine thin intersecting lines (fibrin strands).
Endometrioma: homogeneous low-level internal echoes ‘ground glass’, minimal vascularity, smooth walled. Often bilocular, often bilateral.
Dermoid/teratoma: avascular, usually unilocular but with variable internal structure due to the differentiating cell types, most commonly hair (fine linear dots and dashes) and fluid levels (due to different fluid types). Classically dermoids have shadowing echogenic areas due to calcification.
Invasive malignancy: large irregular solid mass, highly vascular, usually no visible normal ovarian tissue remaining, ascites (defined by IOTA as fluid above the level of the uterine fundus to differentiate from physiological pelvic fluid commonly seen after ovulation).
Management of haemorrhagic cyst
Haemorrhagic cysts often resolve spontaneously.
Repeat ultrasound in 2-3 months can be considered to ensure cyst resolution.
Ideally, this ultrasound should be performed just after a period to prevent confusion with a new corpus luteum.